NCT05479032View on ClinicalTrials.gov

Amantadine for Neuroenhancement in Acute Patients Study

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 1, 2023

Primary Completion Date

October 30, 2024

Study Completion Date

December 31, 2024

Conditions
Disorder of Consciousness
Interventions
DRUG

Amantadine

2x100 mg Amantadine for 3-5 days (dosage can be doubled in case of missing response to treatment after 48 hours)

Trial Locations (1)

72076

RECRUITING

Universitätsklinikum Tübingen, Tübingen

All Listed Sponsors
lead

University Hospital Tuebingen

OTHER